Key Developments: Acasti Pharma Inc (ACST.OQ)

ACST.OQ on NASDAQ Stock Exchange Capital Market

0.56USD
19 Dec 2014
Price Change (% chg)

$-0.01 (-1.41%)
Prev Close
$0.57
Open
$0.57
Day's High
$0.61
Day's Low
$0.55
Volume
22,825
Avg. Vol
47,195
52-wk High
$1.56
52-wk Low
$0.36

Search Stocks

Latest Key Developments (Source: Significant Developments)

Acasti Pharma Inc announces positive top-line pharmacokinetic results
Tuesday, 30 Sep 2014 08:00am EDT 

Acasti Pharma Inc:Announces top-line results for its pharmacokinetic trial evaluating the bioavailability and safety of CaPre on healthy individuals taking single and multiple daily oral doses of the Corporation's new investigational drug candidate.Says it composed of a patent-protected highly concentrated novel omega-3 phospholipid for the prevention and treatment of certain cardiometabolic disorders.  Full Article

Acasti Pharma Inc announces appointment of Chairman
Tuesday, 15 Jul 2014 05:48pm EDT 

Acasti Pharma Inc:Says, at Acasti's Annual & Special Meeting, held on June 19, 2014, shareholders elected slate of directors.Following vote at Board meeting held on July 15, 2014, Jerald J. Wenker was appointed Chairman of Board of Acasti, effective immediately.  Full Article

Acasti Pharma Inc completes phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials
Wednesday, 9 Jul 2014 08:00am EDT 

Acasti Pharma Inc:Completion of two trials, the Phase II double-blind, placebo-controlled (TRIFECTA) study and the Pharmacokinetic (PK) trial.Says results of the Phase II and PK trials are important part of Acasti's on-going discussions with US Food and Drug Administration (FDA) to obtain approval to conduct Phase III trial in the USA.Says primary objective of the TRIFECTA trial is to evaluate the safety and efficacy of CaPre in reducing triglyceride levels in patients with mild to severe hypertriglyceridemia.Upon reaching the number of targeted patients, a planned second blinded interim analysis indicated a significant clinical signal, without any safety concerns.Says given that stopping threshold had been met, the data review committee members recommended that there was sufficient evidence of a treatment effect that warranted the termination of the study.Intends to unblind study and top-line results are expected by end of September with full data coming out in the following quarter.Acasti's Pharmacokinetic trial is designed to evaluate blood profiles and bioavailability in healthy human volunteers taking single and multiple doses of Capre.  Full Article

Acasti announces resignation of Chief Financial Officer
Monday, 16 Jun 2014 07:00am EDT 

Acasti Pharma Inc:Says resignation of Xavier Harland as Chief Financial Officer with immediate effect.  Full Article

Neptune Technologies & Bioressources Inc, Acasti Pharma Inc and NeuroBioPharm Inc announce appointment of interim president and CEO
Friday, 23 May 2014 08:00am EDT 

Neptune Technologies & Bioressources Inc, Acasti Pharma Inc and NeuroBioPharm Inc:Jointly announce the appointment of Andre Godin as interim president and chief executive officer of Neptune, Acasti and NeuroBio with immediate effect.Godin is currently chief financial officer of Neptune.  Full Article

Neptune Technologies & Bioressources Inc, Acasti Pharma Inc and NeuroBioPharm Inc announce resignation of chief executive officer
Monday, 28 Apr 2014 08:00am EDT 

Neptune Technologies & Bioressources Inc, Acasti Pharma Inc and NeuroBioPharm Inc:Jointly announce the resignation of Henri Harland as president and chief executive officer of Neptune, Acasti and NeuroBio with immediate effect.Harland remains a Director of Neptune, Acasti and NeuroBio.Search for a new president and chief executive officer will commence immediately.  Full Article

Neptune Technologies & Bioressources Inc and Acasti Pharma Inc announces final patent infringement settlement and license agreement
Sunday, 27 Apr 2014 09:00pm EDT 

Neptune Technologies & Bioressources Inc and Acasti Pharma Inc:Says it's Neptune subsidiary, signed final and binding patent infringement settlement and license agreement with Enzymotec Ltd. and Enzymotec USA, Inc.That resolves the International Trade Commission's investigation of infringement of Neptune's composition of matter patents.Ans related federal court actions initiated by Neptune against Enzymotec and its distributors, and various patent review proceedings requested by Enzymotec.  Full Article

Acasti Pharma Inc closing of C$2.15 mln private placement of common share
Friday, 7 Feb 2014 08:00am EST 

Acasti Pharma Inc:Closing of a private placement of C$2,150,000 of units of Acasti at a price of C$1.33 per Unit.Says each unit consisting of one Class A share and one common share purchase warrant of Acasti.Says each warrant will entitle the holder to purchase one common share at an exercise price of C$1.60 per warrant share.Says an agent's commission of 2.5 pct of the gross proceeds of the private placement was paid to Euro Pacific Canada Inc.Intends to allocate the proceeds from the private placement for general corporate and working capital purposes.  Full Article

FDA clears Acasti Pharma Inc's investigational new drug submission to conduct pk trial
Thursday, 9 Jan 2014 07:30am EST 

Acasti Pharma Inc:Says U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) submission to initiate a Pharmacokinetic (PK) trial of CaPre in the U.S., having found no objections with the PK trial design, protocol, or safety profile of CaPre.Says PK trial is an open-label, randomized, multiple-dose, single-center, parallel-design study that will evaluate blood profiles and bioavailability of omega-3 phospholipids on 42 healthy volunteers taking single and multiple daily oral doses of 1, 2 and 4 grams of CaPre.  Full Article

Acasti Pharma Inc announces closing of $23 million underwritten offering of units
Tuesday, 3 Dec 2013 10:14am EST 

Acasti Pharma Inc:Says that the closing of its previously announced underwritten public offering of 16,000,000 units.Says at a price of $1.25 per Unit.Says each unit consisting of one Class A share and one Common Share purchase warrant.Says each warrant will entitle the holder to purchase one common share at an exercise price of $1.50 per warrant share.Says prior to the closing, the underwriters exercised their over-allotment option in full to purchase an additional 2,400,000 units, resulting in a total of 18,400,000 units being issued for gross proceeds of approximately $23 million.Says Euro Pacific Canada Inc. acted as book-running manager for the offering, and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc., acted as co-manager.Says Roth Capital Partners, LLC acted as financial advisor for the offering and H.C. Wainwright & Co., LLC acted as advisor.Estimates that the net proceeds from the offering will be approximately $20.8 million, after deducting the underwriting commissions and other offering expenses.Says Acasti intends to allocate the net proceeds from the offering as current Phase II double blind clinical trial, proposed pharmacokinetic trial of CaPre in the United States and the balance for general corporate and other working capital purposes.  Full Article

Search Stocks